| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S12185-020-02829-6 |
| P698 | PubMed publication ID | 32026210 |
| P50 | author | Yusuke Furukawa | Q59691238 |
| P2093 | author name string | Jiro Kikuchi | |
| P2860 | cites work | Induction of t(11;14) IgH enhancer/promoter-cyclin D1 gene translocation using CRISPR/Cas9 | Q91755950 |
| Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies | Q91810574 | ||
| Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7 | Q92266478 | ||
| Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy | Q92284298 | ||
| Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma | Q92350689 | ||
| Mutational processes contributing to the development of multiple myeloma | Q92460202 | ||
| Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia | Q92826117 | ||
| Genomic landscape and chronological reconstruction of driver events in multiple myeloma | Q92832246 | ||
| PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage | Q92883870 | ||
| Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma | Q92893259 | ||
| Impact of acquired del(17p) in multiple myeloma | Q93086330 | ||
| MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells | Q93336711 | ||
| Initial genome sequencing and analysis of multiple myeloma | Q24629117 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma | Q33948719 | ||
| Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. | Q34020965 | ||
| Minor clone provides a reservoir for relapse in multiple myeloma | Q34147170 | ||
| Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma | Q34255215 | ||
| Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. | Q34479418 | ||
| Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations | Q35081172 | ||
| Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma | Q35097105 | ||
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma | Q36055752 | ||
| Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides | Q36141838 | ||
| Clonal competition with alternating dominance in multiple myeloma. | Q36141846 | ||
| Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma | Q36335870 | ||
| Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? | Q36382187 | ||
| The translocation t(4;14) can be present only in minor subclones in multiple myeloma | Q36890185 | ||
| Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma | Q37138519 | ||
| Differential effects of lenalidomide during plasma cell differentiation | Q37317494 | ||
| Heterogeneity of genomic evolution and mutational profiles in multiple myeloma | Q37528285 | ||
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms | Q37564751 | ||
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. | Q37724272 | ||
| Molecular pathogenesis of multiple myeloma. | Q38466422 | ||
| Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation | Q38605030 | ||
| Neutral tumor evolution in myeloma is associated with poor prognosis. | Q38615431 | ||
| Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis | Q38662385 | ||
| Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. | Q38712993 | ||
| Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. | Q38742055 | ||
| The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma | Q38760679 | ||
| Deregulation and Targeting of TP53 Pathway in Multiple Myeloma | Q61449903 | ||
| Immunotherapy in myeloma: how far have we come? | Q61813810 | ||
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis | Q61905635 | ||
| The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma | Q61905638 | ||
| Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells | Q64061199 | ||
| Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s | Q64076943 | ||
| Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop | Q64084639 | ||
| High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma | Q64091867 | ||
| Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. | Q64900417 | ||
| Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. | Q64931827 | ||
| Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation. | Q64965310 | ||
| A model of mutation appropriate to estimate the number of electrophoretically detectable alleles in a finite population* | Q79768452 | ||
| PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma | Q86940848 | ||
| From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells | Q88497827 | ||
| The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma | Q90012448 | ||
| Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma | Q90318029 | ||
| Evolution of Cancer Progression in the Context of Darwinism | Q90784060 | ||
| Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis | Q90884738 | ||
| Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma? | Q91259625 | ||
| Smoldering Multiple Myeloma: To Treat or Not to Treat | Q91266448 | ||
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients | Q91409167 | ||
| EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation | Q91520867 | ||
| Trends in overall survival and costs of multiple myeloma, 2000-2014. | Q38779003 | ||
| Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma | Q38832401 | ||
| Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. | Q38895512 | ||
| Monoclonal antibody therapy in multiple myeloma. | Q38956372 | ||
| Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma | Q39308923 | ||
| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. | Q39560208 | ||
| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody | Q39705098 | ||
| Identification of neutral tumor evolution across cancer types. | Q40093976 | ||
| Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. | Q40633414 | ||
| Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project | Q40769161 | ||
| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing | Q41436943 | ||
| Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. | Q41663752 | ||
| Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival | Q42261210 | ||
| High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide | Q42364304 | ||
| Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma | Q42762683 | ||
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy | Q43024864 | ||
| Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma | Q43151198 | ||
| Somatic mosaicism in chronic myeloid leukemia in remission. | Q43781107 | ||
| Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. | Q44086949 | ||
| Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. | Q45392132 | ||
| Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. | Q46027082 | ||
| Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. | Q46265856 | ||
| Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma | Q47109450 | ||
| The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. | Q47165099 | ||
| Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Q47283493 | ||
| Evolutionary biology of high-risk multiple myeloma | Q47913337 | ||
| Immunopathogenesis and immunotherapy of multiple myeloma. | Q48169937 | ||
| Natural history of t(11;14) multiple myeloma | Q48214992 | ||
| Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. | Q48236775 | ||
| Exome sequencing in tracking clonal evolution in multiple myeloma following therapy | Q48754565 | ||
| Myeloma Cells are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex which Senses Lipopolysaccharide | Q49832507 | ||
| Daratumumab resistance is frequent in advanced stage multiple myeloma patients irrespectively of CD38 expression, and is related to dismal prognosis. | Q49906406 | ||
| Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups | Q50057730 | ||
| Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance | Q50330020 | ||
| Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. | Q51679220 | ||
| Understanding cancer from the stem cells up. | Q52766551 | ||
| Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. | Q53170046 | ||
| Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling. | Q55310350 | ||
| Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma | Q56973515 | ||
| A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma | Q57027518 | ||
| Pomalidomide inhibits PD-L1 to promote anti-tumor immunity | Q57470569 | ||
| Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability | Q57734034 | ||
| Genomic patterns of progression in smoldering multiple myeloma | Q58721686 | ||
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma | Q58792995 | ||
| Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project | Q59329492 | ||
| Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial | Q60923162 | ||
| P433 | issue | 4 | |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 496-511 | |
| P577 | publication date | 2020-02-06 | |
| P1433 | published in | International Journal of Hematology | Q6051416 |
| P1476 | title | Molecular basis of clonal evolution in multiple myeloma | |
| P478 | volume | 111 |
| Q99728301 | CAR T cell therapies for patients with multiple myeloma | cites work | P2860 |
Search more.